Monday, December 23, 2024
HomeTagsJacobio JAB-21822

Jacobio JAB-21822

Jacobio JAB-21822 in Combination with Cetuximab Completes First Dose of Colorectal Cancer Patient in China

Jacobio Pharmaceuticals announced that its KRAS G12C inhibitor JAB-21822 completed the first patient dosing in combination therapy with Cetuximab at Peking University Cancer Hospital...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics